Below are the most recent publications written about "Antidepressive Agents" by people in Profiles.
-
Duarte Y, Quintana-Donoso D, Moraga-Amaro R, Dinamarca I, Lemunao Y, C?rdenas K, Bahamonde T, Barrientos T, Olivares P, Navas C, Carvajal FJ, Santib?nez Y, Castro-Lazo R, Paz Meza M, Jorquera R, G?mez GI, Henke M, Alarc?n R, Gabriel LA, Schiffmann S, Cerpa W, Retamal MA, Simon F, Linsambarth S, Gonzalez-Nilo F, Stehberg J. The role of astrocytes in depression, its prevention, and treatment by targeting astroglial gliotransmitter release. Proc Natl Acad Sci U S A. 2024 Nov 12; 121(46):e2307953121.
-
Chang CY, Park H, Hincapie-Castillo JM, Heldermon CD, Diaby V, Yang S, Wilson DL, Lo-Ciganic WH. Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression. J Manag Care Spec Pharm. 2023 Apr; 29(4):431-445.
-
Korthauer LE, Goveas JS, Rapp SR, Espeland MA, Shumaker SA, Garcia KR, Rossom RC, Garcia L, Tindle HA, Salmoirago-Blotcher E, Wassertheil-Smoller S, Zaslavsky O, Cochrane B, Sink KM, Masaki K, Driscoll I. The relationship between depressive symptoms and subtypes of mild cognitive impairment in post-menopausal women: Results from the Women's Health Initiative Memory Study. Int J Geriatr Psychiatry. 2022 11; 37(11).
-
Fortuna G, Whitmire S, Sullivan K, Alajbeg I, Andabak-Rogulj A, Pedersen AML, Vissink A, di Fede O, Aria M, Jager DJ, Noll J, Jensen SB, Wolff A, Brennan MT. Impact of medications on salivary flow rate in patients with xerostomia: a retrospective study by the Xeromeds Consortium. Clin Oral Investig. 2023 Jan; 27(1):235-248.
-
Healy D, Bahrick A, Bak M, Barbato A, Calabr? RS, Chubak BM, Cosci F, Csoka AB, D'Avanzo B, Diviccaro S, Giatti S, Goldstein I, Graf H, Hellstrom WJG, Irwig MS, Jannini EA, Janssen PKC, Khera M, Kumar MT, Le Noury J, Lew-Starowicz M, Linden DEJ, L?ning C, Mangin D, Melcangi RC, Rodr?guez OWMAAS, Panicker JN, Patacchini A, Pearlman AM, Pukall CF, Raj S, Reisman Y, Rubin RS, Schreiber R, Shipko S, Va?eckov? B, Waraich A. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022; 33(1):65-76.
-
McCarthy MJ, Chen Y, Demodena A, Leckband SG, Fischer E, Golshan S, Suppes T, Kelsoe JR. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. J Psychopharmacol. 2021 Aug; 35(8):992-1002.
-
Reddy HM, Poole JS, Maguire GA, Stahl SM. New Medications for Neuropsychiatric Disorders. Psychiatr Clin North Am. 2020 06; 43(2):399-413.
-
Lu BY, Agapoff JR, Olson DJ, Williams SR, Roller A, Goebert D. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series. J Affect Disord. 2020 02 01; 262:40-42.
-
Tizabi Y, Getachew B, Csoka AB, Manaye KF, Copeland RL. Novel targets for parkinsonism-depression comorbidity. Prog Mol Biol Transl Sci. 2019; 167:1-24.
-
Getachew B, Mendieta L, Csoka AB, Aguilera J, Tizabi Y. Antidepressant effects of C-Terminal domain of the heavy chain of tetanus toxin in a rat model of depression. Behav Brain Res. 2019 09 16; 370:111968.